V79 Chinese hamster lung cells resistant to the bis-alkylator bizelesin are multidrug-resistant
Original Articles Bizelesin, Multidrug Resistance
Received:
Accepted:
- 23 Downloads
- 1 Citations
Abstract
Bizelesin (U-77779) is a highly potent bis-alkylating antitumor agent that is effective against several tumor systems in vitro and in vivo. V79 cells that were 125-to 250-fold resistant to bizelesin developed after constant exposure to gradually increasing concentrations of the drug. Resistant cells exhibited a multidrug-resistant phenotype and genotype as indicated by cross-resistance to several structurally and functionally unrelated drugs, e. g., colchicine, actinomycin D, and Adriamycin, and overexpression of mdr mRNA. Very low levels of cross-resistance to the alkylating, agents cisplatin and melphalan were seen. Multidrug-resistant mouse leukemia (P388/Adriamycin-resistant) and human (KB/vinblastine-resistant) cells were also resistant to bizelesin. Bizelesin resistance was unstable and decreased when cells were grown in the absence of the drug. Resistant and sensitive cell lines had similar levels of glutathione, and bizelesin cytotoxicity for resistant cells was not markedly affected by treatment with buthionine sulfoximine. Cross-resistance between bizelesin and several of its analogs is reported.
Keywords
Colchicine Adriamycin Resistant Cell Actinomycin Sulfoximine
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- 1.Abraham I, Chin K-V, Gottesman MM, Mayo JK, Sampson KE (1990) Transfection of a mutant regulatory subunit gene of cAMP dependent protein kinase increases drug sensitivity and decreased expression of P-glycoprotein. Exp Cell Res 189: 133Google Scholar
- 2.Badiner GJ, Moy BC, Smith KS, Tarpley WG, Groppi VG, Bhuyan BK (1990) P388 leukemia cells resistant to the anthracyline menogaril lack MDR phenotype. Br J Cancer 62: 378Google Scholar
- 3.Bhuyan BK, Newell KA, Crampton SL, Von Hoff DD (1982) CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis and cell survival. Cancer Res 42: 3532Google Scholar
- 4.Bhuyan BK, Smith KS, Adams EG, Petzold GL, McGovren JP (1992) Lethality, DNA alkylation and cell cycle effects of adozelesin (U-73975) on rodent and human cells. Cancer Res 52: 5687Google Scholar
- 5.Bhuyan BK, Smith KS, Kelly RC, Adams EG, Abraham I, Sampson KE (1993) Multidrug resistance is a component of V79 cell resistance to the alkylating agent adozelesin. Cancer Res 53: 1Google Scholar
- 6.Cano-Gauci DF, Riordan JR (1987) Action of calcium antagonists on multidrug resistant cells. Biochem Pharmacol 36: 2115Google Scholar
- 7.Chirgwin JM, Przybyla AE, McDonald RJ, Rutter WJ (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18: 5294Google Scholar
- 8.Church GM, Gilbert W (1984) Genomic sequencing. Proc Natl Acad Sci USA 81: 1991Google Scholar
- 9.DeKoning TD, Kelly RC, Wallace TL, Li LH (1989) Antitumor activity and biochemical effect of three cyclopropyrroloindole analogs. Proc Am Assoc Cancer Res 30: 491Google Scholar
- 10.DeKoning TF, Postmus RJ, Wallace TL, Kelly RC, Li LH (1990) Therapeutic evaluation of three cyclopropapyrroloindole (CPI) analogs against human tumor xenografts. Proc Am Assoc Cancer Res 31: 348Google Scholar
- 11.Feinberg AP, Vogelstein B (1983) A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132: 6Google Scholar
- 12.Hamilton TC, Winker MA, Louis KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKay WM, Young RC, Ozols RF (1985) Augmentation of Adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and-sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34: 2583Google Scholar
- 13.Hurley LH, Reynolds VL, Swenson DH, Petzold GL, Scahill TA (1984) Reaction of the antitumor antibiotics CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science 226: 843Google Scholar
- 14.Johnson RK, Chitnis MP, Embrey WM, Gregory EB (1978) In vivo characteristics of resistance and cross-resistance of an Adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 62: 1535Google Scholar
- 15.Kartner N, Shales M, Riordan JR, Ling V (1983) Daunorubicinresistant, Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res 43: 4413Google Scholar
- 16.Kaye S, Merry S (1985) Tumor cell resistance to anthracyclines—a review. Cancer Chemother Pharmacol 14: 96–103Google Scholar
- 17.Klohs WC, Steinkampf RW, Havlick MJ, Jackson RD (1986) Resistance to anthrapyrazoles and anthracyclines in multidrugresistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonist. Cancer Res 46: 4325Google Scholar
- 18.Ling V, Thompson LH (1974) Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83: 103Google Scholar
- 19.Maniatis T, Frisch EF, Stanbrook J (1982) Molecular cloning — a laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New YorkGoogle Scholar
- 20.Martin DG, Chidester CG, Duchamp DJ, Mizsak SA (1980) Structure of CC-1065 (NSC 298223), a new antitumor antibiotic. J Antibiot 33: 902Google Scholar
- 21.McGovren JP, Clarke GL, Pratt EA, DeKoning TF (1984) Preliminary toxicity studies with the DNA-binding antibiotic CC-1065. J Antibiot 37: 63Google Scholar
- 22.Michell MA, Kelly RC, Wicnienski N, Hatzenbuhler NT, Williams MG, Petzold GL, Slightom JL, Siemieniak DR (1991) Synthesis and DNA cross-linking by a rigid CPI dimer. J Am Chem Soc 113: 8994Google Scholar
- 23.Nakashima K, Nishida K, Nakatsuji S, Akiyama S (1986) Development and application of organic reagents for analysis. VIII. Determination of biochemical thiols with a new fluorogenic thiol selective reagent,N-{p-[2-(6-diethylamino)-benzofuranyl]phenyl] maleimide. Chem Pharm Bull (Tokyo) 34: 1678Google Scholar
- 24.Pastan IH, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC (1988) A retrovirus carrying an, MDR1 cDNA clone confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85: 4486Google Scholar
- 25.Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V (1985) Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316: 817Google Scholar
- 26.Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH (1983) Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67: 905Google Scholar
- 27.Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, Gottesman MM (1986) Human multidrug resistant cell lines: increased mdr-1 expression, can precede gene amplification. Science 232: 643Google Scholar
- 28.Sun D, Hurley LH (1993) Analysis of the monoalkylation and cross-linking sequence specificity of bizelesin, a bifunctional alkylating agent related to (+)-CC-1065. J Am Chem Soc 115: 5925Google Scholar
- 29.Swenson DH, Li LH, Hurley LH, Rokem JS, Petzold GL, Dayton BD, Wallace TL, Lin AH, Krueger WC (1982) Mechanism of interaction of CC-1065 with DNA. Cancer Res 42: 2821Google Scholar
- 30.Teicher BA, Cucchi CA, Lee JB, Flatow JL, Roswosky A, Frei E (1986) Alkylating agents: in vitro studies of cross-resistance patterns in human tumor cell lines. Cancer Res 46: 4379Google Scholar
- 31.Waxman DJ (1990) Glutathione-S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy. A review. Cancer Res 50: 6449Google Scholar
- 32.Zsido TJ, Beerman TA, Meegan RL, Wagnarowski JM, Baker RM (1992) Resistance of CHO cells expressing P-glycoprotein to CPI alkylating agents. Biochem Pharmacol 43: 1817Google Scholar
Copyright information
© Springer-Verlag 1994